证券代码：601633 证券简称：长城汽车 公告编号：2026-011 转债代码：113049 转债简称：长汽转债 长城汽车股份有限公司 2025 年年度业绩快报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 1 月 30 日，长城汽车股份有限公司(以下简称"本公司"或"公司")以书 面传签方式召开了第八届董事会第四十七次会议，全体董事会成员审议并通过了《关于 公司 2025 年年度业绩快报的议案》，表决结果如下：8 票同意，0 票反对，0 票弃权。本 公司 2025 年年度业绩快报情况如下： 一、业绩快报期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 二、2025 年年度主要财务数据和指标（合并财务数据） 单位：人民币亿元 | 项目 | 本报告期 | 上年同期 | | 增减变动幅度 | | --- | --- | --- | --- | --- | | | | | | （％） | | | | 调整前 | 调整后 | 调整后 | | 营业总收入 | 2,227.90 | 2,021.95 ...

证券代码：601995 证券简称：中金公司 公告编号：临 2026-007 本期业绩预告的具体适用情形为：实现盈利，且净利润与上年同期相 比上升 50%以上。 中国国际金融股份有限公司 2025 年年度业绩预增公告 中国国际金融股份有限公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中国国际金融股份有限公司（以下简称"公司"）预计 2025 年年度实 现归属于母公司股东的净利润为人民币 85.42 亿元到人民币 105.35 亿元，与上年 同期相比，将增加人民币 28.47 亿元到人民币 48.40 亿元，同比增加 50%到 85%。 重要内容提示： 扣除非经常性损益事项后，预计 2025 年年度实现归属于母公司股东的 净利润为人民币 84.28 亿元到人民币 103.51 亿元，与上年同期相比，将增加人民 币 27.72 亿元到人民币 46.95 亿元，同比增加 49%到 83%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日（以下简称"本期"）。 （二）业绩预告情 ...

一、本期业绩预告情况 （一）业绩预告期间 证券代码： 603826 证券简称： 坤彩科技 公告编号：2026-002 福建坤彩材料科技股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （二）归属于上市公司股东的净利润：3,514.30 万元。 1、经公司财务部门初步测算，预计 2025 年年度实现归属于上市公司股东的 净利润为-6,500.00 万元到-8,500.00 万元，与上年同期 3,514.30 万元相比，将 出现亏损。 2、经公司财务部门初步测算，预计 2025 年年度实现归属于上市公司股东的 扣除非经常性损益的净利润为-7,500.00 万元到-9,500.00 万元。 3、经公司财务部门初步测算，预计 2025 年年度营业收入为 120,000.00 万元 到 130,000.00 万元,与上年同期 96,989.34 万元相比，将增加 23,010.66 万元到 3 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of 12 million to 18 million yuan for 2025, marking a turnaround from a loss of 186.67 million to 192.67 million yuan year-on-year, an increase of 106.87% to 110.30%[3] - The projected net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be a loss of 55 million to 40 million yuan, a reduction in loss of 153.51 million to 168.51 million yuan year-on-year, representing a decrease in loss of 73.62% to 80.82%[3] - The previous year's net profit attributable to shareholders was a loss of 174.67 million yuan, with a loss of 208.51 million yuan after deducting non-recurring gains and losses[5] Market and Product Performance - The company benefited from the rapid development of the new energy vehicle and energy storage industries, leading to a significant expansion in market demand for new energy materials[7] - The prices of the company's main products, vinyl carbonate (VC) and fluorinated ethylene carbonate (FEC), have significantly increased, contributing to an improvement in gross profit margins[7] - The company experienced a substantial increase in sales volume of its main products, which positively impacted its operating performance[7] - Increased investment income from external projects has also contributed to the significant rise in overall investment returns compared to the previous year[7] Financial Reporting and Risks - The financial data in this earnings forecast has not been audited by a registered accountant and is based on preliminary calculations by the company's finance department[8] - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report for 2025[9]

Revenue Projections - The company expects to achieve an annual revenue of between 796.49 million and 828.99 million yuan for 2025, representing a year-on-year increase of 49.45% to 55.55%[2]. - The significant revenue growth is primarily driven by increased sales of pharmaceuticals, particularly after the inclusion of recombinant thrombin in the national medical insurance drug list[4]. - The commercial launch of Jikaxitinib tablets during the reporting period has also contributed to revenue growth[5]. Net Loss Estimates - The projected net loss attributable to the parent company for 2025 is estimated to be between -191.39 million and -139.60 million yuan, an increase in loss of 1.77 million to 53.56 million yuan compared to the previous year[2]. - The expected net loss attributable to the parent company after deducting non-recurring gains and losses is projected to be between -237.87 million and -172.53 million yuan, an increase in loss of 1.37 million to 66.71 million yuan compared to the previous year[2]. - The company anticipates that both net profits before and after deducting non-recurring gains and losses will remain negative, with increased losses attributed to rising sales and research and development expenses[5]. Financial Data and Auditing - The financial data provided in the earnings forecast has not been audited by registered accountants[6]. - Investors are advised to note that the forecast data is preliminary and the final audited financial data will be disclosed in the official 2025 annual report[7].

证券代码：688166 证券简称：博瑞医药 公告编号：2026-003 博瑞生物医药（苏州）股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 三、本期业绩变化的主要原因 2025 年公司归属于母公司所有者的净利润预计同比减少 67.28%到 78.17%， 归属于母公司所有者的扣除非经常性损益的净利润预计同比减少 86.21%到 1 97.62%，主要受流感趋势变化、竞争格局变化、客户阶段性商业需求波动等影响， 使得当期营业收入及产品毛利额减少，以及在建工程陆续完工转固带来计提折旧 增加，同时创新药等研发投入加大使得研发费用等期间费用同比有所增加。 公司聚焦代谢领域，通过前瞻性布局，公司在多靶点联合用药及创新给药频 率等关键方向储备了丰富且具有竞争力的产品管线，旨在为患者提供更全面、更 个性化的治疗方案与用药选择。公司在研项目取得诸多进展，截至本公告披露日 ...

证券代码：600730 证券简称：中国高科 公告编号：临 2026-002 中国高科集团股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本期业绩预告情况 预计 2025 年年度实现营业收入 7,804 万元，扣除与主营业务无关的业务收 入和不具备商业实质的收入后的营业收入为 7,709 万元，低于 3 亿元。 （三）本次业绩预告数据未经注册会计师审计。 1 中国高科集团股份有限公司（简称"中国高科"或"公司"）预计 2025 年年度净利润为负值；同时，利润总额、净利润或者扣除非经常性损益 后的净利润孰低者为负值，且扣除与主营业务无关的业务收入和不具备 商业实质的收入后的营业收入低于 3 亿元。 公司预计 2025 年年度实现利润总额-15,291 万元到-12,743 万元，预计 2025 年年度实现归属于母公司所有者的净利润-13,589 万元到-11,324 万 元；预计归属于母公司所有者的扣除非经常性损益后的净利润为-10,888 万元到-7,509 万元。 （ ...

Financial Performance - The total operating revenue for 2025 reached CNY 550,074.55 million, representing a year-on-year increase of 10.94%[2] - The net profit attributable to shareholders of the parent company was CNY -196,891.19 million, an improvement of 21.81% compared to the previous year[5] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, was CNY -204,758.65 million, improving by 20.83% year-on-year[5] - The basic earnings per share were CNY -0.14, compared to CNY -0.18 in the previous year[2] - The weighted average return on net assets improved to -21.76%, an increase of 0.53 percentage points from the previous year[2] Assets and Equity - Total assets at the end of the reporting period were CNY 2,679,408.43 million, a decrease of 9.46% from the beginning of the period[3] - Shareholders' equity attributable to the parent company was CNY 806,518.78 million, down 19.62% from the beginning of the period[3] Operational Improvements - The company implemented measures to enhance quality management, optimize the supply chain, and control financial costs, contributing to improved gross profit margin and net profit[7] - The cash flow from operating activities turned positive, indicating a continuous improvement in overall operational performance[7] Audit and Reporting - The financial data presented are preliminary and subject to final audit, with potential discrepancies in the annual report[9]

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 21 million and 30 million yuan, an increase of 55.5 million to 64.5 million yuan compared to the previous year [3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 5 million and 7.5 million yuan, an increase of 56.5 million to 58.9 million yuan year-over-year [3]. - The previous year's net profit attributable to shareholders was a loss of 34.5 million yuan, with a total profit of -5.33 million yuan [4]. Factors Influencing Financial Performance - The company has improved its financial performance due to increased product acceptance and effective cost control in sales, management, and R&D expenses [5]. - There were no significant impairment losses on equity investments in the current reporting period, unlike the previous year [5]. Earnings Forecast and Risks - The company has not identified any major uncertainties that could significantly affect the accuracy of this earnings forecast [6]. - The earnings forecast is based on preliminary calculations and has not yet been audited by certified public accountants [6]. - Investors are advised to pay attention to investment risks as the data provided is preliminary and subject to change upon the release of the audited annual report [7].

Financial Projections - The company expects to achieve operating revenue of between 670 million and 700 million yuan in 2025, representing a year-on-year growth of 41.18% to 47.50%[3] - The net profit attributable to the parent company is projected to be between -26 million and -18 million yuan, indicating continued losses compared to the previous year[3] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is expected to be between -30 million and -22 million yuan[3] - In the previous year, the operating revenue was 474.585 million yuan, with a net profit of -1.974 million yuan[5] - The performance forecast is based on preliminary calculations by the finance department and has not been audited by a registered accountant[10] - Investors are advised to be cautious as the forecast data is preliminary and the final audited financial data will be disclosed in the 2025 annual report[11] Cost and Profitability Factors - The increase in costs during the capacity ramp-up phase is a significant factor affecting profitability, driven by high labor and depreciation costs[8] - The increase in revenue has led to a rise in accounts receivable, resulting in higher credit impairment losses compared to the previous year[9] Market Focus and Development - The company plans to focus on markets such as AI high-speed connectors, optical modules, and automotive electronics, while accelerating overseas market expansion[9] - The company aims to enhance its online platform www.wantpcb.com to improve PCB prototyping experiences and achieve differentiated development[9]